Earnings
Rigel 3Q Loss Narrows On Lower Costs
SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. said Tuesday its third-quarter loss narrowed as the development-stage biotechnology company completed two midstage studies in its rheumatoid-arthritis program.
The company lost $26.7 million, or 70 cents per share, compared with a loss of $37.7 million, or $1.03 per share, a year ago. There was no reported revenue during either quarter and the company still does not have a product on the market. Analysts polled by Thomson Reuters, on average, expected a loss of 58 cents per share on revenue $3.8 million. Rigel said stock-based compensation fell by about half, while operating expenses fell 31 percent to $26.7 million. The company ended the quarter with cash, cash equivalents and available for sale securities of $156.1 million. Rigel is developing treatments for rheumatoid arthritis, asthma, allergies and cancer. Partners on various programs include Serono SA, Pfizer Inc. and Merck & Co.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet